UBS Group
BLUE

UBS Group’s bluebird bio BLUE Stock Holding History

UBS Group’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,804
Closed -$253K – 10272
2025
Q1 		$253K Sell
51,804
-54,498
-51% -$328K ﹤0.01% 6377
2024
Q4 		$887K Buy
106,302
+101,347
+2,045% +$886K ﹤0.01% 5400
2024
Q3 		$51.4K Buy
4,955
+1,527
+45% +$25.4K ﹤0.01% 6799
2024
Q2 		$67.5K Sell
3,428
-7,528
-69% -$151K ﹤0.01% 6452
2024
Q1 		$280K Sell
10,956
-23,311
-68% -$598K ﹤0.01% 5620
2023
Q4 		$946K Buy
34,267
+19,873
+138% +$1.21M ﹤0.01% 4546
2023
Q3 		$875K Sell
14,394
-6,565
-31% -$461K ﹤0.01% 4195
2023
Q2 		$1.38M Sell
20,959
-6,373
-23% -$466K ﹤0.01% 3921
2023
Q1 		$1.74M Sell
27,332
-6,749
-20% -$771K ﹤0.01% 3574
2022
Q4 		$4.72M Buy
34,081
+27,164
+393% +$3.83M ﹤0.01% 2556
2022
Q3 		$877K Buy
6,917
+6,777
+4,841% +$767K ﹤0.01% 3855
2022
Q2 		$12K Sell
140
-40,883
-100% -$3.17M ﹤0.01% 7636
2022
Q1 		$3.98M Buy
41,023
+21,252
+107% +$2.8M ﹤0.01% 2763
2021
Q4 		$3.95M Buy
19,771
+5,118
+35% +$1.21M ﹤0.01% 3080
2021
Q3 		$3.63M Buy
14,653
+13,654
+1,367% +$3.9M ﹤0.01% 3010
2021
Q2 		$413K Sell
999
-4,484
-82% -$1.78M ﹤0.01% 4878
2021
Q1 		$2.14M Buy
5,483
+3,290
+150% +$1.62M ﹤0.01% 3497
2020
Q4 		$1.23M Sell
2,193
-595
-21% -$377K ﹤0.01% 3850
2020
Q3 		$1.95M Buy
2,788
+155
+6% +$121K ﹤0.01% 3072
2020
Q2 		$2.08M Buy
2,633
+807
+44% +$609K ﹤0.01% 2837
2020
Q1 		$1.09M Buy
1,826
+577
+46% +$562K ﹤0.01% 3279
2019
Q4 		$1.42M Sell
1,249
-4,390
-78% -$4.77M ﹤0.01% 3883
2019
Q3 		$6.71M Buy
5,639
+2,484
+79% +$3.79M ﹤0.01% 2112
2019
Q2 		$5.2M Sell
3,155
-106
-3% -$183K ﹤0.01% 2302
2019
Q1 		$6.65M Sell
3,261
-3,860
-54% -$6.8M ﹤0.01% 1981
2018
Q4 		$9.15M Buy
7,121
+3,830
+116% +$5.87M ﹤0.01% 1642
2018
Q3 		$6.22M Sell
3,291
-860
-21% -$1.78M ﹤0.01% 2168
2018
Q2 		$8.44M Buy
4,151
+49
+1% +$112K ﹤0.01% 1887
2018
Q1 		$9.07M Buy
4,102
+1,600
+64% +$4.07M ﹤0.01% 1786
2017
Q4 		$5.77M Sell
2,502
-1,545
-38% -$3.14M ﹤0.01% 2213
2017
Q3 		$7.2M Buy
4,047
+1,847
+84% +$2.58M ﹤0.01% 1868
2017
Q2 		$2.99M Buy
2,200
+1,729
+367% +$2.09M ﹤0.01% 2624
2017
Q1 		$554K Sell
471
-3,093
-87% -$3.15M ﹤0.01% 3963
2016
Q4 		$2.85M Buy
3,564
+1,663
+87% +$1.32M ﹤0.01% 2595
2016
Q3 		$1.67M Buy
1,901
+1,357
+249% +$983K ﹤0.01% 3010
2016
Q2 		$305K Buy
544
+12
+2% +$6.8K ﹤0.01% 4249
2016
Q1 		$293K Sell
532
-10,730
-95% -$6.59M ﹤0.01% 4199
2015
Q4 		$9.37M Buy
11,262
+10,877
+2,825% +$10.9M 0.01% 1448
2015
Q3 		$428K Sell
385
-958
-71% -$1.75M ﹤0.01% 4034
2015
Q2 		$2.93M Sell
1,343
-1,302
-49% -$2.65M ﹤0.01% 2608
2015
Q1 		$4.14M Sell
2,645
-3,387
-56% -$4.47M ﹤0.01% 2232
2014
Q4 		$7.17M Buy
+6,032
New +$4.03M 0.01% 1780

Other funds holding BLUE

Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's BLUE Position: Q2 2025 in Review

UBS Group sold out of bluebird bio (BLUE) in Q2 2025, closing a stake of 51,804 shares — an estimated $253K sold.

UBS Group first reported a position in BLUE in Q4 2014 and held it in 42 quarters. The position peaked at $9.37M in Q4 2015. 3 funds tracked by Wall St. Rank hold BLUE as of Q2 2025.

  • UBS Group reported no remaining bluebird bio position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 51,804 bluebird bio shares in Q2 2025, an estimated $253K.
  • UBS Group first reported a position in bluebird bio in Q4 2014 and held it in 42 quarters.
  • UBS Group's bluebird bio position peaked at $9.37M in Q4 2015.
  • 3 funds tracked by Wall St. Rank held bluebird bio as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.